QUEST DIAGNOSTICS INC

Quest Diagnostics has a liquidity position with a current ratio of 1.18, indicating a moderate ability to meet short-term obligations, though it is close to the minimum comfort range. The company's debt-to-equity ratio is 0.77, suggesting a relatively balanced capital structure. Free cash flow of $164 million in Q1 2026 supports operational flexibility, but net cash is negative after subtracting total debt, signaling potential liquidity constraints. Profitability metrics show a return on equity of 3.42% and a return on assets of 1.51%, both below the industry median for healthcare diagnostics firms. These figures suggest that Quest Diagnostics is underperforming in terms of capital efficiency and asset utilization compared to its peers. The company's revenue is concentrated in the DIS segment, which accounts for the majority of its operations. Geographically, Quest Diagnostics has a broad U.S. footprint, but the input data does not specify regional revenue breakdowns. The company's services are primarily delivered under the Quest Diagnostics brand and other acquired brands, including AmeriPath and Dermpath Diagnostics. Quest Diagnostics reported Q1 2026 revenue of $2.895 billion, with a year-over-year growth rate of 2.1%. The company's outlook for FY 2026 includes a projected revenue increase of 3.5%, driven by growth in its Collaborative Lab Solutions offering and continued adoption of AI and digital pathology solutions. The company's management signals indicate a focus on share repurchases, with recent accelerated share repurchase arrangements. Risk factors include ongoing legal investigations by the Northern District of Georgia and the Texas Attorney General’s Office, which could result in material financial exposure. The company also faces medium dilution risk, with shares outstanding at 112 million and potential for further dilution through future offerings. The risk assessment highlights liquidity concerns, particularly the current ratio and net cash position, which could limit the company's ability to respond to unexpected financial demands. Recent events include the FASB's new accounting standard impacting internal-use software, which may affect the company's financial reporting. Additionally, the company is under scrutiny for compliance and billing practices, particularly in relation to Medicaid in Texas.